2021
Uptake and effectiveness of checkpoint inhibitor therapy among trial-ineligible patients with advanced solid malignancies.
Parikh R, Min E, Wileyto E, Riaz F, Gross C, Cohen R, Hubbard R, Long Q, Mamtani R. Uptake and effectiveness of checkpoint inhibitor therapy among trial-ineligible patients with advanced solid malignancies. Journal Of Clinical Oncology 2021, 39: e18595-e18595. DOI: 10.1200/jco.2021.39.15_suppl.e18595.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsNon-ICI therapyAdvanced solid malignanciesICI monotherapyPerformance statusEarly mortalitySolid malignanciesFlatiron Health electronic health record-derived databaseElectronic health record-derived databaseFirst-line immune checkpoint inhibitorsNon-small cell lungInverse probabilityICI combination therapyTrial-ineligible patientsCheckpoint inhibitor therapyECOG performance statusPoor performance statusRetrospective cohort studyPhase III trialsCommunity oncology practicesPivotal clinical trialsMean survival timeTime-varying hazard ratiosPart of standardCheckpoint inhibitors
2020
Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies.
Parikh R, Cohen R, Min E, Wileyto E, Riaz F, Gross C, Long Q, Mamtani R. Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies. Journal Of Clinical Oncology 2020, 38: e19316-e19316. DOI: 10.1200/jco.2020.38.15_suppl.e19316.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced solid malignanciesEastern Cooperative Oncology Group performance statusUrothelial cell carcinomaRenal cell carcinomaNon-frail patientsFrail patientsSolid malignanciesHepatocellular carcinomaCell carcinomaFlatiron Health electronic health record-derived databaseStage IV non-small cell lung cancerElectronic health record-derived databaseFirst-line immune checkpoint inhibitorsFirst-line ICI treatmentFirst-line systemic therapyImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitorsRetrospective cohort studyFirst-line useElixhauser Comorbidity IndexCell lung cancerMultivariable logistic regressionYears of treatment
2019
Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice.
Parikh R, Galsky M, Gyawali B, Riaz F, Kaufmann T, Cohen A, Adamson B, Gross C, Meropol N, Mamtani R. Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice. Journal Of Clinical Oncology 2019, 37: 395-395. DOI: 10.1200/jco.2019.37.7_suppl.395.Peer-Reviewed Original ResearchAdvanced urothelial cell carcinomaPoor performance statusEnd of lifeSystemic therapyDay of deathQuarterly proportionPoor PSStudy periodFlatiron Health databaseSystemic therapy initiationCheckpoint inhibitor therapyFavorable toxicity profileUrothelial cell carcinomaDays of lifeSecular trend analysisChemotherapy initiationChemotherapy useCPI useReal-world practiceTherapy initiationInhibitor therapyPerformance statusPS 0Cell carcinomaNational guidelines